Sanofi Fires Up Late-Stage R&D After Growth Rekindled in Fourth Quarter
This article was originally published in The Pink Sheet Daily
Nine late-stage products are expected to lead Sanofi’s future evolution into a developer primarily of biologics, including alirocumab for hypercholesterolemia, dupilumab for atopic dermatitis and asthma, and sarilumab for rheumatoid arthritis.
You may also be interested in...
Sanofi shows solid growth in emerging markets in the fourth quarter, including an impressive 35.1% gain in China. Teva in transition offers scant detail on emerging markets, but hints larger deals possible in 2014.
In the latest win for Samsung Bioepis, the Korean company will help develop and manufacture a late-stage insulin glargine candidate with Merck.
Rater-blinded design for multiple sclerosis claim netted an approval in Europe but a rejection by FDA, which was concerned about bias related to open label studies.